Novartis AG

Questions about tolerability and cost of treatment need answering before clinical practice should change

Former BCMA head named education minister

Head of Novartis Oncology gives an insider view on drug development; warns that as therapies help cancer patients live longer, long-term care will fall to family physicians

Phase II study of relaxin draws criticism, but editorialists agree results warrant further study

Phase II study of relaxin draws criticism, but editorialists agree results warrant further study

Novartis' Aclasta (zoledronic acid injection) is now approved for use as a once-yearly intravenous (IV) infusion in the prevention and treatment of corticosteroid-induced osteoporosis, to increase bone mineral density.